| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Yu Jeffrey | Chief Medical Officer, Director | 6385 OLD SHADY OAK ROAD, SUITE 250, EDEN PRAIRIE | /s/ Robert Golden, Attorney-in-Fact | 26 Nov 2025 | 0001991132 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ONMD | Common Stock | Conversion of derivative security | $546,368 | +479,270 | +17% | $1.14 | 3,242,465 | 17 Jun 2025 | Direct | F1 |
| transaction | ONMD | Common Stock | Conversion of derivative security | $1,298,078 | +1,828,279 | +56% | $0.7100 | 5,070,744 | 19 Jun 2025 | Direct | F2 |
| transaction | ONMD | Common Stock | Purchase | $700,000 | +1,666,666 | +33% | $0.4200 | 6,737,410 | 20 Jun 2025 | Direct | F3 |
| transaction | ONMD | Common Stock | Purchase | $12,705 | +16,500 | +0.24% | $0.7700 | 6,753,910 | 19 Aug 2025 | Direct | F4 |
| transaction | ONMD | Common Stock | Purchase | $11,550 | +15,000 | +0.22% | $0.7700 | 6,768,910 | 21 Aug 2025 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $9,975 | +13,300 | +0.2% | $0.7500 | 6,782,210 | 25 Aug 2025 | Direct | F5 |
| transaction | ONMD | Common Stock | Purchase | $119,612 | +173,350 | +2.6% | $0.6900 | 6,955,560 | 26 Aug 2025 | Direct | F6 |
| transaction | ONMD | Common Stock | Purchase | $14,748 | +21,374 | +0.31% | $0.6900 | 6,976,934 | 27 Aug 2025 | Direct | F7 |
| transaction | ONMD | Common Stock | Purchase | $13,600 | +17,000 | +0.24% | $0.8000 | 6,993,934 | 28 Aug 2025 | Direct | F8 |
| transaction | ONMD | Common Stock | Purchase | $8,930 | +10,890 | +0.16% | $0.8200 | 7,004,824 | 29 Aug 2025 | Direct | F9 |
| transaction | ONMD | Common Stock | Purchase | $20,671 | +24,319 | +0.35% | $0.8500 | 7,029,143 | 02 Sep 2025 | Direct | F10 |
| transaction | ONMD | Common Stock | Purchase | $9,453 | +11,670 | +0.17% | $0.8100 | 7,040,813 | 03 Sep 2025 | Direct | F11 |
| transaction | ONMD | Common Stock | Purchase | $10,275 | +11,810 | +0.17% | $0.8700 | 7,052,623 | 04 Sep 2025 | Direct | F12 |
| transaction | ONMD | Common Stock | Purchase | $1,806 | +2,100 | +0.03% | $0.8600 | 7,054,723 | 05 Sep 2025 | Direct | F13 |
| transaction | ONMD | Common Stock | Purchase | $637 | +700 | +0.01% | $0.9100 | 7,055,423 | 18 Sep 2025 | Direct | F14 |
| transaction | ONMD | Common Stock | Purchase | $1,112 | +1,250 | +0.02% | $0.8900 | 7,056,673 | 19 Sep 2025 | Direct | F15 |
| transaction | ONMD | Common Stock | Purchase | $380 | +400 | +0.01% | $0.9500 | 7,057,073 | 22 Sep 2025 | Direct | F16 |
| transaction | ONMD | Common Stock | Purchase | $5,301 | +5,700 | +0.08% | $0.9300 | 7,062,773 | 23 Sep 2025 | Direct | F17 |
| transaction | ONMD | Common Stock | Purchase | $17,544 | +17,200 | +0.24% | $1.02 | 7,079,973 | 24 Sep 2025 | Direct | F18 |
| transaction | ONMD | Common Stock | Purchase | $1,288 | +1,250 | +0.02% | $1.03 | 7,081,223 | 25 Sep 2025 | Direct | F19 |
| transaction | ONMD | Common Stock | Award | $0 | +200,000 | +2.8% | $0.000000 | 7,281,223 | 24 Nov 2025 | Direct | F20 |
| transaction | ONMD | Common Stock | Award | $0 | +45,000 | +0.62% | $0.000000 | 7,326,223 | 26 Nov 2025 | Direct | F21 |
| holding | ONMD | Common Stock | 1,311,970 | 17 Jun 2025 | By trust for children | F22 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ONMD | Senior Secured Convertible Note | Conversion of derivative security | $546,368 | -479,270 | -100% | $1.14 | 0 | 17 Jun 2025 | Common Stock | 479,270 | $1.14 | Direct | F1, F8 |
| transaction | ONMD | Warrants (Right to Buy | Purchase | $178 | +5,946 | $0.0300 | 5,946 | 09 May 2025 | Common Stock | 5,946 | $11.50 | Direct |
| Id | Content |
|---|---|
| F1 | On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance. |
| F2 | On June 19, 2025, the issuer entered into an agreement with the reporting person to convert an aggregate of approximately $1.3 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans. |
| F3 | On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,666,666 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $700,000 in gross proceeds to the issuer. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.76 to $0.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.74 to $0.75, inclusive. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.66 to $0.79, inclusive. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.68 to $0.72, inclusive. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.78 to $0.81, inclusive. |
| F9 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.79 to $0.85, inclusive. |
| F10 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.83 to $0.88, inclusive. |
| F11 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.77 to $0.86, inclusive. |
| F12 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.84 to $0.92, inclusive. |
| F13 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.84 to $0.90, inclusive. |
| F14 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.94, inclusive. |
| F15 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.88 to $0.92, inclusive. |
| F16 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.99, inclusive. |
| F17 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.91 to $0.96, inclusive. |
| F18 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.05, inclusive. |
| F19 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.04, inclusive. |
| F20 | Represents restricted stock units ("RSUs") granted under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") as employment compensation. RSUs vest as to one-third (1/3) of the RSUs on the first anniversary of the vesting start date of January 1, 2025, with the remaining RSUs vesting thereafter in equal quarterly installments on the last day of each fiscal quarter over the subsequent two (2) years, provided that the recipient remains in continuous service through each vesting date. |
| F21 | Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
| F22 | The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose. |